02:28 PM EST, 11/20/2025 (MT Newswires) -- Jaguar Health's ( JAGX ) family company, Napo Pharmaceuticals, said Thursday it submitted an amended protocol to the US Food and Drug Administration for its ongoing placebo-controlled clinical trial of crofelemer in pediatric patients with microvillus inclusion disease, or MVID.

The company said it expects that the amended protocol, together with results from its investigator-initiated trial of crofelemer in the United Arab Emirates, if positive, could support an expedited FDA review and potential approval for the treatment.

Shares of Jaguar Health ( JAGX ) were down more than 8% in recent trading.

Price: 1.24, Change: -0.11, Percent Change: -8.15